Citius Oncology, Inc.: 10-Q filed 2022-11-28
What Citius Oncology, Inc. reported in its quarterly report filed 2022-11-28 (fiscal Q3 2022): 9 published measures, 28 facts as tagged in accession 0001493152-22-033847.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-11-28
- Fiscal period
- fiscal Q3 2022
- Accession
- 0001493152-22-033847 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Oncology, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 256,745 | USD | |
| At 2021-12-31 | 126,422 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | -10,113 | USD | |
| At 2022-06-30 | -10,113 | USD | |
| At 2022-03-31 | -10,113 | USD | |
| At 2021-12-31 | -10,113 | USD | |
| At 2021-09-30 | -10,113 | USD | |
| At 2021-06-30 | -10,113 | USD | |
| At 2021-03-31 | -9,389 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-03-01 to 2021-09-30 | -10,113 | USD | 214 |
| 2021-04-01 to 2021-06-30 | -724 | USD | 91 |
| 2021-03-01 to 2021-03-31 | -9,389 | USD | 31 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | -10,113 | USD | |
| At 2021-12-31 | -10,113 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 1,500,000 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 1,500,000 | shares | 273 |
| 2021-07-01 to 2021-09-30 | 1,500,000 | shares | 92 |
| 2021-03-01 to 2021-09-30 | 1,500,000 | shares | 214 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 0 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | 0 | USD/shares | 273 |
| 2021-07-01 to 2021-09-30 | 0 | USD/shares | 92 |
| 2021-03-01 to 2021-09-30 | -0.01 | USD/shares | 214 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 266,858 | USD | |
| At 2021-12-31 | 136,535 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 1,725,000 | shares | |
| At 2021-12-31 | 1,725,000 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 24,827 | USD | |
| At 2021-12-31 | 24,827 | USD |
Inspect the source
- Entity
- Citius Oncology, Inc. / CIK 0001851484
- Captured
- 2026-09-21T17:32:34.031Z
- SEC response SHA-256
1e8c39a029a9529c1971ba7b07551c1ef4dd6de443d807231887851f2cef037a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001851484.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))